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Background and aims: To elicit utility values for five health states corresponding to increasing severity of hepatic
encephalopathy, from members of the general public in the UK. The health states studied were Conn grades 0, 1, 2,
3 and 4.
Methods: Interviewer-administered time trade-off (TTO) and standard gamble (SG) utilities were elicited for the five
health states from a random sample of 200 members of the general public in the UK, using health state descriptions
validated by clinicians and members of the general public.
Results: Respondents’ mean age was 49.5 years and 49% were female. Mean utilities were 0.962 (TTO) and 0.915 (SG)
for Conn grade 0; 0.912 (TTO) and 0.837 (SG) for Conn grade 1; 0.828 (TTO) and 0.683 (SG) for Conn grade 2; 0.691 (TTO)
and 0.489 (SG) for Conn grade 3; and 0.429 (TTO) and 0.215 (SG) for Conn grade 4. The TTO and SG values between the
five Conn grades were significantly different (p < 0.001). Additionally, the TTO value was significantly higher than the SG
value for the corresponding state (p <0.0001).
Conclusion: These findings quantify how different Conn grades and level of response to treatment may impact on the
health-related quality of life of patients with hepatic encephalopathy. There were greater preference values for lower
levels of disease, with the highest value associated with Conn grade 0. These health state preference values can be
used to estimate the outcomes of different interventions for hepatic encephalopathy in terms of quality-adjusted life
years.
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Hepatic encephalopathy (HE) is a reversible neuropsychi-
atric disorder caused by an accumulation of toxins in the
bloodstream that are normally removed by the liver. HE
encompasses a spectrum of neuropsychiatric abnormal-
ities seen in patients with established liver disease, and is
most commonly associated with liver cirrhosis [1,2].
HE can be graded using the Conn grade (also called the
West Haven classification) in which higher scores indicate
higher disease severity. Grade 0 represents no personality
or behavioural abnormality detected. Grade 1 represents
lack of awareness, euphoria or anxiety, shortened attention* Correspondence: julian.guest@catalyst-health.co.uk
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unless otherwise stated.span, impaired performance of addition. Grade 2 repre-
sents lethargy or apathy, minimal disorientation for time
or place, subtle personality change, inappropriate behav-
iour, impaired performance of subtraction. Grade 3 repre-
sents somnolence to semi stupor but responsive to verbal
stimuli, confusion, gross disorientation. Grade 4 repre-
sents coma (unresponsive to verbal or noxious stimuli)
[2-4]. Approximately 70% of patients with liver cirrhosis
present with subclinical or mild HE, and 23-40% progress
to a more severe form of the disease [5-7].
In 2011, the ISHEN (International Society for Hepatic
Encephalopathy and Nitrogen Metabolism) classification
system [8] was proposed, but is yet to be fully adopted
by the clinical community. The system classifies patients
as being “unimpaired” (no clinical neurophysiological/
neuropsychometric changes), or having “covert” HEtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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“overt” HE (i.e. clinically relevant HE or HE with a Conn
grade of 2, 3 or 4). After an overt episode, patients usually
return to an unimpaired or minimal HE state and this is
considered to constitute a state of remission.
HE is associated with diminished health-related quality
of life (HRQoL) across both physical and mental do-
mains [9-14] compared to the general population and is
similar to that observed in patients with other chronic
diseases, such as congestive heart failure [9]. The impair-
ment in HRQoL, as measured by the Chronic Liver Dis-
ease Questionnaires (CLDQ), found that patients who
experience overt breakthrough HE have a significantly
lower overall HRQoL score than patients who maintain
remission from overt HE [14].
Utilities are a measure of an individual’s preference for,
or desirability of, a specific level of health status or spe-
cific health outcome [15]. Quantifying the subjective im-
pact of treatment on patients, by estimating their utility
preference for different health states, is key in comparing
the cost-effectiveness of alternative treatments. Estimat-
ing patients’ health status utility enables preferences to
be quantified for selected clinical outcomes, and life
expectancy to be quality-adjusted.
Instruments that are used to measure an individual’s
health status can be generic or disease-specific. More-
over, the valuation of health states can be undertaken
using a variety of techniques including time trade-off
(TTO) and standard gamble (SG) methods. In TTO, re-
sponders are given a choice between two health profiles;
a particular health state for a given number of years and
full health for a shorter period of time. In effect they are
asked to trade between quality of life and length of life.
The method tries to establish where they are indifferent
between the two by varying the amount of time spent in
full health. In SG, respondents are given the choice
between two alternatives; one being a health state with
certainty and the other being a gamble with two possible
outcomes that involve two different health states with
particular probabilities attached to each of them. The
probabilities attached to the health states are varied until
the responder is indifferent between the two alternatives.
Generally, TTO is widely seen as an acceptable com-
promise between simplicity and theoretical rigour [16].
Published utilities for the different Conn grade health
states were not available and the only available published
estimates were for the remission and overt states. One
study reported a utility value of 0.60 for the HE health
state using SG methodology among a sample of nine pa-
tients with decompensated cirrhosis [17,18]. The corre-
sponding value for patients with compensated cirrhosis
was 0.80 [18]. The other studies used a panel of hepatol-
ogists to elicit utility values for a number of health states
for liver disease, including HE [19,20]. Accordingly, thisstudy aimed to elicit preference values for the five indi-
vidual Conn grade health states from randomly selected
members of the general public in the UK using standard
gamble (SG) and time trade-off (TTO) techniques.
Methods
Health states
Descriptions of five HE health states (i.e. Conn grade 0,
Conn grade 1, Conn grade 2, Conn grade 3 and Conn
grade 4) were developed in collaboration with clinicians
using published literature [4,8,21,22]. Each health state
described the typical patient experience across several
domains including symptoms, treatment, response, man-
agement and prognosis, enabling a balanced description
across all five health states. The health states were re-
fined after iterative review by clinicians and piloting the
descriptions among a sample of 20 members of the gen-
eral public in London, UK. Each health state description
(Table 1) is a lay interpretation of the original wording
in the cited references, in order to paint a meaningful
picture of the respective Conn grades to members of the
general public.
Study respondents
A sample of 267 randomly selected members of the general
public at six different locations across Greater London, UK
were invited to participate in the study. Of these, 67 sub-
jects declined. Hence, the study was undertaken among a
sample of 200 randomly selected members of the general
public using non-probability sampling. The interviewers
were unaware whether the individuals contacted had any
family or friends suffering from HE. Respondents had to be
aged between 35 and 65 years of age with or without any
liver disease. Potential respondents were excluded if they
were not English-speaking, or if they had apparent cogni-
tive impairment, or if in the interviewers' opinion they
were incapable of understanding the task. Recruitment
occurred during January 2013 and none of the respondents
received any remuneration for their participation.
Data collection and analysis
Data were collected through individual, face-to-face inter-
views, which were conducted using an interview script. At
the start of the interview the nature of the questionnaire
was explained, after which participants were asked a range
of socio-demographic questions about themselves. Parti-
cipants were then asked to read a short, non-technical
description of HE and the five different health states.
Afterwards, they were asked what proportion of their
remaining lifetime they would be willing to sacrifice in
return for not living with the symptoms associated with
each of the five health states being evaluated. The TTO
approach was open-ended and the interviewers did not
use any props.
Table 1 Health state descriptions for the five HE health
states
Non-technical description of hepatic encephalopathy
➢ The liver is an organ in the abdomen that processes nutrients and
fluids and removes toxins and harmful substances from the blood.
➢ Liver cirrhosis is the end result of liver damage caused by alcohol
abuse or hepatitis or poor diet or obesity or some bile duct
diseases.
➢ Individuals with liver cirrhosis generally present with an enlarged
liver and specific blood tests and scans may be required to confirm
a liver problem. A liver biopsy may also be required.
➢ Damage caused by liver cirrhosis is permanent and the liver cannot
return to normal. Therefore, the aim of treatment is to prevent
further damage and manage any complications.
➢ Patients with severe liver cirrhosis can develop hepatic
encephalopathy. Symptoms include forgetfulness, confusion,
personality changes, problems with muscles and movement of
limbs and possibly coma. There are five grades of hepatic
encephalopathy and the symptoms affect a patient to varying
degrees depending on the grade of disease.
➢ Treatment usually involves medication and changes to diet and
lifestyle. If the symptoms cannot be controlled a liver transplant
may be required.
➢ An estimated 58% of patients usually die within one year of
experiencing an episode of hepatic encephalopathy and 77% have
usually died within three years.
Grade 0
➢ Patients can experience tiredness, itching, loss of appetite, nausea,
weight loss and bruising of the skin.
➢ Patients may also find it difficult to pay attention and their reaction
times may be slower than normal, so it can take longer to complete
usual daily activities.
➢ Patients might see their doctor and receive general advice and
minimal treatment.
➢ Very few patients who remain in Grade 0 will die.
Grade 1
➢ Patients have the same symptoms as those in Grade 0. However,
they may also experience a slight lack of awareness, anxiety, feelings
of well-being or happiness.
➢ These patients may also find it harder to pay attention and have
difficulty sleeping and performing usual daily activities.
➢ Patients are more likely to see their doctor, who would try to
establish the cause of the worsening symptoms, and receive
general advice and appropriate medical treatment.
➢ Very few patients who remain in Grade 1 will die.
Grade 2
➢ Patients in Grade 2 have the same symptoms as those in Grade 1. In
addition they may feel very tired, lack energy and become forgetful.
➢ These patients will take longer than normal to perform usual daily
activities and may become disoriented and detached from family
and friends.
➢ Their speech may be slow or slurred and they may not respond to
questions as normal.
➢ They may be irritable and more child-like in their behaviour.
➢ Patients may be hospitalised for a few days for tests to try to
establish the cause of the worsening symptoms, and receive
appropriate supportive care and medical treatment. Afterwards,
patients may or may not return to the way they were before.
Table 1 Health state descriptions for the five HE health
states (Continued)
➢ An estimated 20% of patients in Grade 2 will die.
Grade 3
➢ Patients in Grade 3 have the same symptoms as those in Grade 2. In
addition, they may feel very drowsy or sleepy for long periods or
confused and feel as if their brain is unable to function as usual.
➢ They may be unable to perform usual daily activities, such as
reading and writing, and may be unable to respond if someone
speaks to them.
➢ Their body may not be responsive and their speech may be slow or
slurred.
➢ Patients will be hospitalised for a few days or a few weeks for tests
to try to establish the cause of the worsening symptoms, and
receive appropriate supportive care and medical treatment.
Afterwards, patients may or may not return to the way they were
before.
➢ An estimated 56% of patients in Grade 3 will die.
Grade 4
➢ Patients in Grade 4 will be unconscious in a coma.
➢ These patients will be hospitalised for a few weeks or maybe even
months.
➢ They will be given tests to try to establish the cause of the
worsening symptoms, and receive appropriate supportive care,
including oxygen to help them breathe, as well as medical
treatment.
➢ These patients are unable to perform any daily activities while they
are in a coma.
➢ Patients who survive may or may not return to the way they were
before.
➢ An estimated 75% of patients in Grade 4 will die.
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values using the TTO approach, values were also elicited
using the SG approach. This involved asking participants
to choose between the certainty of living with the symp-
toms associated with each health state or gambling on a
treatment with two possible outcomes: successful treat-
ment or death. The search procedure used in the SG
approach was simple titration and the interviewers used
diagrams to help respondents visualise the trade-offs
involved. No other props were used. Participants were
also asked to rate their current health on a horizontal
visual analogue scale (range, 0 to 1).
Using the methodology described by Hammerschmidt
et al. [23], utility values (ranging from 1.0 for perfect
health to 0 for death) were obtained for the five different
health states. Differences between groups were tested for
statistical significance using analysis of variance (ANOVA)
comparing pair-wise means at the p < 0.05 level and
Tukey’s honestly significant difference (HSD) multiple
comparison post-hoc analysis to determine which means
were similar and which were different.
The preference values associated with the five different
health states were stratified by baseline variables including
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income, preference value for their current health, whether
they had any illness or knew someone with liver disease.
Linear regression was performed to assess the relationship
between all these independent variables and the respon-
dents’ preference values for each Conn grade.Results
The study sample comprised 200 participants who were
interviewed in Greater London. The respondents’ mean
age was 49.5 (95% CI: 48.1; 50.9) years and 49% were
female. Three percent of respondents had an illness at the
time of the interview and 7% knew individuals with liver
disease. Overall, the participants rated their current health
with a utility value of 0.93 (95% CI: 0.91; 0.94) using a hori-
zontal visual analogue scale (VAS). Linear regression dem-
onstrated that the respondents’ preference value for their
current health was not affected by their age, gender, mari-
tal status, employment status, annual income, whether
they had any illness or knew someone with liver disease.
Using the TTO approach, Conn grade 0 was the most
preferred health state, with a mean utility of 0.962 in the
overall sample (Table 2). The second-most preferred
health state was Conn grade 1 followed by Conn grade 2
and Conn grade 3 (mean utility in the overall sample
were 0.912, 0.828 and 0.691 respectively). The least pre-
ferred health state was Conn grade 4 with a mean utility
of 0.429 in the overall sample. The mean utility scores
between the five Conn grades were different (p < 0.001,
ANOVA; Table 3). However, Tukey’s HSD multiple com-
parison post-hoc analysis showed that the mean utility
score for Conn grades 0 and 1 were not significantly dif-
ferent, but Conn grades 1, 2, 3 and 4 were significantly
different from one another (Table 4).
Similar trends were observed using SG (Tables 2 and
3), although the utility values were all significantly lower
than those derived by TTO (p <0.001). Additionally, the
utility values for each state were significantly different
from one another (p <0.001; Table 4)Table 2 Mean utilities (95% confidence intervals) for five HE
Mean utilit
Conn grade 0 Conn grade 1
Utilities elicited
Using TTO
Whole cohort 0.962 0.912
(0.952; 0.972) (0.896; 0.929)
Utilities elicited
Using SG
Whole cohort 0.915 0.837
(0.897; 0.932) (0.816; 0.858)Mean utility values elicited from respondents, strati-
fied by their gender, age, whether they knew someone
with liver disease, marital status, employment status and
annual income is shown in Tables 5 and 6.
Linear regression demonstrated that respondents’ gender,
annual income, preference value for their current health,
whether they had any illness or knew someone with liver
disease did not affect their TTO preference values as the
significance value was >0.05. When these independent vari-
ables were excluded from the regression model it was
found that the TTO values elicited from divorced/separated
respondents were ~0.07 lower than those elicited from
single, married, cohabiting and widowed respondents
(p <0.05). Additionally, the values elicited from retired
respondents were ~0.41 higher than those elicited from
those who were employed, unemployed and students
(p <0.02). Respondents’ age influenced their preference
value for Conn grades 3 and 4; the elicited values were
reduced by 0.01 for each year of age (p < 0.02). Prefer-
ence values for Conn grades 0, 1 and 2 were unaffected
by respondents’ age. Linear regression also showed that
respondents’ preference values for any of the health
states elicited by SG were not affected by their age, gen-
der, marital status, employment status, annual income,
preference value for their current health or whether
they knew someone with liver disease. When these in-
dependent variables were excluded from the regression
model the respondents’ SG preference values for Conn
grade 4 were found to be influenced by whether they
had any illness. The values elicited by those with any
illness were ~0.2 higher than those elicited from the
other respondents (p = 0.02).
Discussion
Patients in remission from HE have an underlying risk of
experiencing breakthrough overt HE episodes. Moreover, if
not prevented, episodes of HE can reoccur and progress in
severity. Therefore, over the course of the condition, a pa-
tient’s HRQoL is likely to decline at any time, depending on
the patient’s underlying risk of experiencing a breakthroughhealth states
ies (95% confidence intervals) for
Conn grade 2 Conn grade 3 Conn grade 4
0.828 0.691 0.429
(0.803; 0.852) (0.656; 0.726) (0.371; 0.487)
0.683 0.489 0.215
(0.657; 0.709) (0.459; 0.519) (0.190; 0.240)
Table 3 Analysis of variance (ANOVA)
Sum of squares Degrees of freedom Mean square F value Significance
TTO values
Between groups 36.567 4 9.142 158.636 0.000
Within groups 57.339 995 0.058
Total 93.906 999
SG values
Between groups 63.715 4 15.929 516.367 0.000
Within groups 30.693 995 0.031
Total 94.408 999
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tient’s HRQoL to be quantified. Additionally, the preference
values elicited in this study will enable a direct comparison
between different levels of treatment response to HE, and
a more accurate calculation of quality-adjusted life years
(QALYs) in economic evaluations of HE treatments.
The mean baseline health status of our sample derived
using a VAS was 0.93. Only 3% of our sample had an
illness at the time of the interviews. Hence, the health
status of our sample was consistent with that reported in
the published literature for subjects with a mean age of
48.9 years with no health condition. The mean EQ-5D
score was reported to be 0.946 for those with no health
condition and 0.843 for those of a similar age irrespective
of health status [24]. Utilities were also elicited from our
sample using a VAS for the five health states being studied
and found to be 0.75 for Conn grade 0, 0.58 for Conn
grade 1, 0.40 for Conn grade 2, 0.20 for Conn grade 3 and
0.09 for Conn grade 4. These values were lower than the
utilities elicited by TTO and SG. This is consistent with
the findings of others who, after a review of utilities across
995 chronic and acute health states, found a strong tendency
for VAS to yield lower values than SG and TTO [25].
The utility values obtained using SG were different
from those obtained using TTO. Such differences are ex-
pected because values elicited by SG are likely to be af-
fected by the respondents’ attitudes toward risk. This is
consistent with our finding that respondents’ preference
values elicited by SG were influenced by whether they
had an illness at the time of the interview. Conversely,
values elicited by TTO are likely to be affected by re-
spondents’ time preferences [16]. This is consistent with
our finding that respondents’ preference values elicited
by TTO were influenced by time-dependent variables.
The TTO preference values for the two most critical
health states (i.e. Conn grades 3 and 4) were influenced
by their age. They were also influenced by whether the
respondents were retired. Additionally, differences in
utility values between Conn grades elicited by TTO are
likely to be smaller than the differences between Conn
grades elicited by SG. Hence, it is likely that cost perQALY values that are estimated using utilities elicited by
TTO will be larger than corresponding values that are
estimated using utilities elicited by SG.
This study was subject to a number of limitations.
Firstly, interviews with patients were not included as part
of the health state development process for practical rea-
sons, although feedback from patients would have facili-
tated validation of the health state descriptions. Instead,
the study relied on contributions from clinicians, based on
the West Haven Classification, published literature and
clinical experience, and piloting among members of the
general public to validate the health states descriptions.
Undoubtedly, validating utility estimates among a popula-
tion of patients with HE in the future may be advanta-
geous. Secondly, as required by the TTO approach, it was
assumed that the relationship between the duration of liv-
ing in a health state and an individual’s utility value for that
health state was independent. This assumption may not be
valid since a study using EQ-5D health states found that
preferences decline with increasing duration of remaining
in a severe health state [26]. Further studies are required
to assess whether this assumption is valid for health state
valuations in HE using a TTO approach and whether the
elicited utility values overestimate true preferences for the
five health states. Thirdly, a non-probability sampling tech-
nique was used to interview a target population of 200
subjects from across Greater London. We would have pre-
ferred to employ a probabilistic sampling method. How-
ever, due to time constraints it was not feasible or practical
to undertake random sampling. Hence, a purposive, non-
probability sampling technique was adopted. The advan-
tage of this sampling method was that a sufficient number
of subjects could be interviewed in the limited time avail-
able. However, the subjects who participated in this study
may not be sufficiently representative of the target popula-
tion of the UK as a whole. Notwithstanding this, some of
our previous utility elicitation studies have been conducted
in up to eight different locations across the UK and prefer-
ence values did not vary across the country [27,28]. More-
over, we have found in previous studies that a minimum of
165 subjects per group is sufficient to detect differences at












Significance 95% Confidence Interval
Lower bound Upper bound
TTO values
0 1 0.049 0.024 0.240 -0.016 0.115
2 0.134 0.024 0.000 0.069 0.200
3 0.271 0.024 0.000 0.205 0.337
4 0.533 0.024 0.000 0.467 0.599
1 0 -0.049 0.024 0.240 -0.115 0.016
2 0.085 0.024 0.004 0.019 0.150
3 0.221 0.024 0.000 0.156 0.287
4 0.484 0.024 0.000 0.418 0.549
2 0 -0.134 0.024 0.000 -0.200 -0.069
1 -0.085 0.024 0.004 -0.150 -0.019
3 0.137 0.024 0.000 0.071 0.202
4 0.399 0.024 0.000 0.333 0.464
3 0 -0.271 0.024 0.000 -0.337 -0.205
1 -0.221 0.024 0.000 -0.287 -0.156
2 -0.137 0.024 0.000 -0.202 -0.071
4 0.262 0.024 0.000 0.196 0.328
4 0 -0.533 0.024 0.000 -0.599 -0.467
1 -0.484 0.024 0.000 -0.549 -0.418
2 -0.399 0.024 0.000 -0.464 -0.333
3 -0.262 0.024 0.000 -0.328 -0.196
SG values
0 1 0.078 0.018 0.000 0.030 0.126
2 0.232 0.018 0.000 0.184 0.280
3 0.426 0.018 0.000 0.378 0.474
4 0.700 0.018 0.000 0.652 0.748
1 0 -0.078 0.018 0.000 -0.126 -0.030
2 0.154 0.018 0.000 0.106 0.202
3 0.348 0.018 0.000 0.300 0.396
4 0.622 0.018 0.000 0.574 0.670
2 0 -0.232 0.018 0.000 -0.280 -0.184
1 -0.154 0.018 0.000 -0.202 -0.106
3 0.194 0.018 0.000 0.146 0.242
4 0.468 0.018 0.000 0.420 0.516
3 0 -0.426 0.018 0.000 -0.474 -0.378
1 -0.348 0.018 0.000 -0.396 -0.300
2 -0.194 0.018 0.000 -0.242 -0.146
4 0.274 0.018 0.000 0.226 0.322
4 0 -0.700 0.018 0.000 -0.748 -0.652
1 -0.622 0.018 0.000 -0.670 -0.574
2 -0.468 0.018 0.000 -0.516 -0.420
3 -0.274 0.018 0.000 -0.322 -0.226
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Table 5 Mean utilities (95% confidence intervals) for five HE health states, stratified by socio-demographic parameters,
using TTO
Mean utilities (95% confidence intervals) for
Conn grade 0 Conn grade 1 Conn grade 2 Conn grade 3 Conn grade 4
Respondents’ gender
Male (n = 101) 0.97 (0.96; 0.98) 0.93 (0.91; 0.95) 0.84 (0.80; 0.87) 0.69 (0.65; 0.74) 0.45 (0.38; 0.53)
Female (n = 99) 0.95 (0.93; 0.97) 0.90 (0.87; 0.92) 0.82 (0.79; 0.85) 0.69 (0.64; 0.74) 0.41 (0.32; 0.49)
Respondents’ age
30-39 years (n = 44) 0.95 (0.92; 0.97) 0.90 (0.87; 0.94) 0.83 (0.78; 0.88) 0.75 (0.70; 0.81) 0.58 (0.50; 0.66)
40-49 years (n = 43) 0.96 (0.94; 0.98) 0.90 (0.87; 0.93) 0.82 (0.78; 0.86) 0.69 (0.63; 0.75) 0.45 (0.32; 0.58)
50-59 years (n = 79) 0.97 (0.95; 0.98) 0.92 (0.89; 0.95) 0.81 (0.77; 0.85) 0.65 (0.58; 0.71) 0.34 (0.24; 0.45)
≥60 years (n = 34) 0.98 (0.95; 1.00) 0.93 (0.89; 0.98) 0.87 (0.80; 0.94) 0.63 (0.57; 0.81) 0.32 (0.23; 0.55)
Respondents had an illness
No (n = 194) 0.96 (0.95; 0.97) 0.91 (0.89; 0.93) 0.83 (0.80; 0.85) 0.69 (0.66; 0.73) 0.43 (0.37; 0.49)
Yes (n = 6) 0.97 (0.92; 1.00) 0.92 (0.83; 1.00) 0.85 (0.71; 0.99) 0.66 (0.47; 0.85) 0.45 (0.18; 0.72)
Respondent knew someone with liver disease
No (n = 187) 0.96 (0.95; 0.97) 0.91 (0.90; 0.93) 0.83 (0.81; 0.86) 0.69 (0.66; 0.73) 0.44 (0.38; 0.50)
Yes (n = 13) 0.95 (0.91; 0.99) 0.88 (0.82; 0.93) 0.78 (0.71; 0.85) 0.66 (0.53; 0.78) 0.28 (0.09; 0.46)
Respondents’ marital status
Married (n = 98) 0.98 (0.97; 0.99) 0.94 (0.92; 0.95) 0.85 (0.82; 0.89) 0.72 (0.67; 0.76) 0.45 (0.38; 0.53)
Co-habiting (n = 33) 0.95 (0.92; 0.98) 0.89 (0.85; 0.93) 0.79 (0.73; 0.85) 0.67 (0.59; 0.75) 0.47 (0.35; 0.59)
Single (n = 31) 0.95 (0.92; 0.98) 0.91 (0.85; 0.96) 0.83 (0.77; 0.88) 0.74 (0.66; 0.81) 0.47 (0.28; 0.65)
Divorced/separated (n = 37) 0.94 (0.91; 0.97) 0.87 (0.82; 0.93) 0.78 (0.71; 0.86) 0.60 (0.49; 0.70) 0.31 (0.15; 0.47)
Widowed (n = 1) 1.00 1.00 1.00 1.00 0.23
Respondents’ employment status
Employed full-time (n = 135) 0.96 (0.95; 0.98) 0.91 (0.89; 0.93) 0.82 (0.79; 0.85) 0.67 (0.63; 0.71) 0.43 (0.36; 0.49)
Self-employed (n = 23) 0.98 (0.96; 1.00) 0.96 (0.93; 0.99) 0.87 (0.82; 0.92) 0.74 (0.66; 0.82) 0.49 (0.36; 0.63)
Employed part-time (n = 21) 0.95 (0.91; 0.99) 0.91 (0.84; 0.98) 0.86 (0.76; 0.96) 0.70 (0.56; 0.84) 0.39 (0.18; 0.59)
Retired (n = 6) 0.99 (0.97; 1.00) 0.98 (0.95; 1.00) 0.98 (0.95; 1.00) 0.92 (0.82; 1.00) 0.70 (0.60; 0.81)
Unemployed (n = 4) 0.94 (0.86; 1.00) 0.93 (0.85; 1.00) 0.84 (0.71; 0.97) 0.71 (0.43; 0.98) 0.40 (0.09; 0.72)
Student (n = 11) 0.91 (0.84; 0.99) 0.82 (0.71; 0.92) 0.72 (0.62; 0.83) 0.65 (0.49; 0.81) 0.26 (0.00; 0.70)
Respondents’ annual income*
<£15000 (n = 13) 0.95 (0.89; 1.00) 0.92 (0.82; 1.00) 0.89 (0.79; 0.98) 0.83 (0.72; 0.93) 0.48 (0.10; 0.85)
£15,000-£25,000 (n = 20) 0.97 (0.94; 0.99) 0.91 (0.87; 0.95) 0.86 (0.79; 0.92) 0.78 (0.69; 0.87) 0.47 (0.30; 0.64)
£25,001-£35,000 (n = 89) 0.96 (0.94; 0.97) 0.90 (0.88; 0.93) 0.81 (0.78; 0.85) 0.66 (0.61; 0.71) 0.43 (0.35; 0.51)
>£35,000 (n = 75) 0.97 (0.95; 0.99) 0.92 (0.90; 0.95) 0.83 (0.79; 0.87) 0.68 (0.62; 0.74) 0.41 (0.31; 0.51)
*3 respondents declined to provide their annual income.
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different health states, if they exist.
Notwithstanding these limitations, this is the first study
to estimate preference values for the different Conn grades
of HE. The only published cost-effectiveness analysis of
competing therapies for HE used a utility value of 0.6 elic-
ited using SG derived from patients with complicated cir-
rhosis as a proxy for overt HE [17]. Other reported utility
values for liver disease are those for patients with end-
stage disease awaiting liver transplantation in the US, who
have an estimated utility of 0.67 and 0.57 elicited usingTTO and SG respectively [29]. In another study using the
Health Utility Index 2, US patients with chronic liver
disease with and without cirrhosis were reported to have a
utility of 0.72 and 0.85 respectively [30]. Conversely, the
utility of Iranian patients with decompensated cirrhosis
was estimated to be 0.55 elicited using SG [31]. In a
systematic review of health state utilities for liver disease,
patients with hepatitis C virus who had decompensated
cirrhosis were estimated to have a utility of 0.79 elicited
using TTO, which was 0.19 higher than utility scores elic-
ited using a VAS [32]. Clearly there is variation in utility
Table 6 Mean utilities (95% confidence intervals) for five HE health states, stratified by socio-demographic parameters,
using SG
Mean utilities (95% confidence intervals) for
Conn grade 0 Conn grade 1 Conn grade 2 Conn grade 3 Conn grade 4
Respondents’ gender
Male (n = 101) 0.93 (0.90; 0.95) 0.86 (0.83; 0.89) 0.70 (0.67; 0.74) 0.51 (0.47; 0.56) 0.23 (0.20; 0.27)
Female (n = 99) 0.90 (0.87; 0.93) 0.82 (0.79; 0.85) 0.66 (0.63; 0.70) 0.46 (0.42; 0.51) 0.19 (0.16; 0.23)
Respondents’ age
30-39 years (n = 44) 0.88 (0.82; 0.94) 0.81 (0.74; 0.87) 0.69 (0.62; 0.76) 0.50 (0.43; 0.57) 0.20 (0.15; 0.26)
40-49 years (n = 43) 0.91 (0.88; 0.94) 0.83 (0.79; 0.87) 0.65 (0.60; 0.70) 0.45 (0.39; 0.51) 0.19 (0.14; 0.24)
50-59 years (n = 79) 0.93 (0.91; 0.94) 0.84 (0.81; 0.87) 0.68 (0.64; 0.72) 0.48 (0.43; 0.52) 0.21 (0.17; 0.25)
≥60 years (n = 34) 0.93 (0.90; 0.97) 0.88 (0.84; 0.92) 0.72 (0.66; 0.77) 0.55 (0.48; 0.62) 0.27 (0.21; 0.33)
Respondents had an illness
No (n = 194) 0.91 (0.90; 0.93) 0.83 (0.81; 0.86) 0.68 (0.65; 0.71) 0.48 (0.45; 0.51) 0.21 (0.18; 0.23)
Yes (n = 6) 0.90 (0.81; 0.99) 0.90 (0.85; 0.95) 0.80 (0.71; 0.89) 0.63 (0.55; 0.72) 0.43 (0.30; 0.56)
Respondent knew someone with liver disease
No (n = 187) 0.91 (0.89; 0.93) 0.83 (0.81; 0.86) 0.68 (0.65; 0.71) 0.48 (0.45; 0.51) 0.21 (0.19; 0.24)
Yes (n = 13) 0.93 (0.90; 0.97) 0.87 (0.81; 0.93) 0.75 (0.68; 0.83) 0.58 (0.49; 0.68) 0.27 (0.17; 0.36)
Respondents’ marital status
Married (n = 98) 0.93 (0.91; 0.95) 0.85 (0.83; 0.88) 0.70 (0.67; 0.74) 0.52 (0.48; 0.56) 0.24 (0.20; 0.27)
Co-habiting (n = 33) 0.89 (0.83; 0.95) 0.81 (0.74; 0.87) 0.64 (0.57; 0.71) 0.44 (0.36; 0.52) 0.19 (0.13; 0.25)
Single (n = 31) 0.89 (0.82; 0.96) 0.85 (0.77; 0.92) 0.73 (0.64; 0.81) 0.54 (0.46; 0.62) 0.22 (0.14; 0.30)
Divorced/separated (n = 37) 0.91 (0.88; 0.94) 0.82 (0.78; 0.86) 0.64 (0.58; 0.70) 0.42 (0.36; 0.47) 0.18 (0.13; 0.22)
Widowed (n = 1) 0.90 0.70 0.40 0.20 0.10
Respondents’ employment status
Employed full-time (n = 135) 0.92 (0.91; 0.94) 0.84 (0.82; 0.86) 0.69 (0.66; 0.72) 0.49 (0.46; 0.53) 0.22 (0.19; 0.25)
Self-employed (n = 23) 0.87 (0.78; 0.96) 0.81 (0.72; 0.90) 0.67 (0.57; 0.77) 0.47 (0.38; 0.56) 0.20 (0.11; 0.30)
Employed part-time (n = 21) 0.93 (0.88; 0.98) 0.83 (0.77; 0.88) 0.66 (0.58; 0.74) 0.48 (0.37; 0.59) 0.18 (0.11; 0.25)
Retired (n = 6) 0.95 (0.88; 1.00) 0.90 (0.81; 0.99) 0.75 (0.58; 0.92) 0.60 (0.47; 0.73) 0.32 (0.18; 0.45)
Unemployed (n = 4) 0.88 (0.83; 0.92) 0.75 (0.62; 0.88) 0.55 (0.35; 0.75) 0.38 (0.23; 0.52) 0.25 (0.08; 0.42)
Student (n = 11) 0.85 (0.67; 1.00) 0.81 (0.64; 0.98) 0.70 (0.55; 0.85) 0.52 (0.38; 0.66) 0.17 (0.08; 0.26)
Respondents’ annual income*
<£15000 (n = 13) 0.85 (0.69; 1.00) 0.80 (0.65; 0.95) 0.66 (0.51; 0.82) 0.55 (0.43; 0.68) 0.19 (0.10; 0.29)
£15,000-£25,000 (n = 20) 0.89 (0.79; 0.99) 0.83 (0.73; 0.93) 0.73 (0.62; 0.84) 0.54 (0.41; 0.66) 0.23 (0.13; 0.33)
£25,001-£35,000 (n = 89) 0.92 (0.90; 0.94) 0.84 (0.82; 0.87) 0.69 (0.66; 0.73) 0.50 (0.46; 0.55) 0.24 (0.20; 0.28)
>£35,000 (n = 75) 0.93 (0.91; 0.94) 0.84 (0.82; 0.87) 0.67 (0.63; 0.71) 0.45 (0.41; 0.50) 0.19 (0.15; 0.22)
*3 respondents declined to provide their annual income.
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ease. Hence, further research should consider estimating
utility values for the different Conn grades from patients
with HE using a probabilistic sampling method.
In conclusion, this study indicates greater preference
values for lower levels of disease, with the highest value
associated with Conn grade 0. Further, this study dem-
onstrates that deeper levels of treatment responses may
impact to a greater extent on the health-related quality
of life of patients with HE. These health state preferencevalues can be used to estimate the outcomes of interven-
tions for HE in terms of quality-adjusted life years.
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